SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials

INTRODUCTION: Gliflozins are recommended as first-line treatment in patients with heart failure and/or cardiovascular comorbidities and are demonstrated to reduce atrial fibrillation (AF) occurrence. However, it is not well known which gliflozin yields the larger cardioprotection in terms of AF occurrence reduction. Hence, we aimed to compare data regarding AF recurrence associated with different gliflozins. METHODS: An accurate search of online scientific libraries (from inception to June 1, 2023) was performed. Fifty-nine studies were included in the meta-analysis involving 108 026 patients, of whom 60 097 received gliflozins and 47 929 received placebo. RESULTS: Gliflozins provided a statistically significant reduction of AF occurrence relative to standard of care therapy in the overall population (relative risks RR: 0.8880, 95% CI: 0.8059; 0.9784, p = .0164) and in patients with diabetes and cardiorenal diseases (RR: 0.8352, 95% CI: 0.7219; 0.9663, p = .0155). Dapagliflozin significantly decreased AF occurrence as compared to placebo (0.7259 0.6337; 0.8316, p < .0001) in the overall population, in patients with diabetes (RR: 0.2482, 95% CI: 0.0682; 0.9033, p = .0345), with diabetes associated with cardiorenal diseases (RR: 0.7192, 95% CI: 0.5679; 0.9110, p = .0063) and in the subanalysis including studies with follow-up ≥1 year (RR: 0.7792, 95% CI: 0.6508; 0.9330, p = .0066). No significant differences in terms of AF protection were found among different gliflozins. CONCLUSIONS: Dapagliflozin use was associated with significant reduction in AF risk as compared to placebo in overall population and patients with diabetes, whereas the use of other gliflozins did not significantly reduce AF occurrence.